KLF12 overcomes anti-PD-1 resistance by reducing galectin-1 in cancer cells.
Yujia ZhengHao ZhangChu XiaoZiqin DengTao FanBo ZhengChunxiang LiJie He
Published in: Journal for immunotherapy of cancer (2023)
T-cell intratumoral infiltration, and targeting the KLF12/Gal-1 axis may serve as a novel therapeutic target for patients with immunotherapy resistance.